Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-Mpl, produces functional human platelets in vitro

Stem Cells
E S ChoiJ Chen

Abstract

Platelet formation, occurring from bone marrow or lung megakaryocytes, has been difficult to study mechanistically. Recombinant human megakaryocyte growth and development factor (rHuMGDF), a recently described cytokine, has now been used to establish an in vitro system in which this important and little understood process occurs. CD34+ cells cultured with rHuMGDF develop into megakaryocytes which form long cytoplasmic extensions (proplatelets) that fragment into platelet-sized particles (in vitro platelets). Morphologically, in vitro and human plasma-derived platelets (control platelets) are virtually identical with respect to size, dense granule distribution and ultrastructural features. Functionally, in vitro and control platelets have similar aggregation and activation responses, and similarly incorporate mepacrine into dense granules. These findings suggest that rHuMGDF is sufficient to generate platelet-synthesizing megakaryocytes from CD34+ cells and provide an experimental setting in which the study of human platelet formation can be adequately performed.

References

Jan 1, 1978·American Journal of Hematology·M A LichtmanP A Santillo
Jan 1, 1990·International Journal of Cell Cloning·K OgataM J Murphy
Nov 15, 1985·Analytical Biochemistry·L A FitzgeraldD R Phillips
Feb 1, 1972·British Journal of Haematology·J F MustardM A Packham
Jan 1, 1981·American Journal of Hematology·G Scurfield, J M Radley
May 1, 1981·British Journal of Haematology·M Tavassoli, M Aoki
Sep 2, 1994·Science·A L GurneyM W Moore
Jun 16, 1994·Nature·F WendlingW Vainchenker
Jun 1, 1993·British Journal of Haematology·C L Erickson-MillerM J Murphy

❮ Previous
Next ❯

Citations

May 20, 1998·Biotherapy·F WendlingW Vainchenker
Jan 17, 2002·International Journal of Hematology·J Li, D J Kuter
Dec 1, 1995·Current Opinion in Biotechnology·P Hunt, M Foote
Jan 28, 1999·Leukemia Research·E Archimbaud, X Thomas
May 7, 1998·Transfusion Science·L A Harker
Apr 1, 1996·Current Opinion in Biotechnology·P C CollinsW M Miller
Dec 3, 1999·The International Journal of Biochemistry & Cell Biology·W S Alexander
Dec 26, 2001·Cytokine & Growth Factor Reviews·Amy E GeddisKenneth Kaushansky
Feb 13, 2001·British Journal of Haematology·A MathurJ Erusalimsky
Jan 1, 1996·Annual Review of Cell and Developmental Biology·S S WatowichH F Lodish
Aug 30, 2008·American Journal of Respiratory Cell and Molecular Biology·Fernando A BozzaGuy A Zimmerman
Jul 30, 2008·Journal of Molecular Neuroscience : MN·Chaneun NamM Sue O'Dorisio
Jan 1, 1996·Stem Cells·K Clarke, R L Basser
Jan 1, 1996·Stem Cells·T Kato
Jul 1, 1998·International Reviews of Immunology·W S Alexander
Dec 8, 2009·Transfusion Medicine Reviews·Jo-Anna ReemsSijie Sun
Apr 9, 2005·British Journal of Haematology·Christof Dame, Anton Heinz Sutor
Jan 27, 2011·Journal of Biomedical Materials Research. Part a·Vipuil KishoreHoward W T Matthew
Nov 5, 1997·Transfusion Medicine Reviews·A M FareseT J MacVittie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.